The FDA has issued an Emergency Use Authorization for KINERET for the treatment of COVID-19 in hospitalized adults with positive results of COVID-19 viral testing with pneumonia requiring supplemental oxygen who are at risk of progressing to severe respiratory failure, and likely to have an elevated plasma soluble urokinase plasminogen activator receptor (suPAR). KINERET is not approved for this use.

Learn more

Two overlapping squares

Looking for additional support?

An animated electrical socket that reads “IL-1” in the top socket, with a KINERET® (anakinra)-branded plug in the bottom socket

KINERET® (anakinra) blocks the interleukin-1 (IL-1) receptor to help protect against autoinflammatory events1

IL-1 is a proinflammatory cytokine that plays a key role in autoinflammation.2 Uncontrolled IL-1 activity can lead to chronic and life-threatening systemic inflammation.1,3,4

Learn more about the role of IL-1 in autoinflammation.

KINERET® (anakinra) blocks the interleukin-1 (IL-1) receptor to help protect against autoinflammatory events1

Support for your patients and practice.